Mechanism of action of lenalidomide in hematological malignancies
<p>Abstract</p> <p>Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the n...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-08-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/36 |
| _version_ | 1819028569259507712 |
|---|---|
| author | Kotla Venumadhav Goel Swati Nischal Sangeeta Heuck Christoph Vivek Kumar Das Bhaskar Verma Amit |
| author_facet | Kotla Venumadhav Goel Swati Nischal Sangeeta Heuck Christoph Vivek Kumar Das Bhaskar Verma Amit |
| author_sort | Kotla Venumadhav |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.</p> |
| first_indexed | 2024-12-21T06:00:27Z |
| format | Article |
| id | doaj.art-e0793a6d30db468da523b46da125b658 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-21T06:00:27Z |
| publishDate | 2009-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-e0793a6d30db468da523b46da125b6582022-12-21T19:13:46ZengBMCJournal of Hematology & Oncology1756-87222009-08-01213610.1186/1756-8722-2-36Mechanism of action of lenalidomide in hematological malignanciesKotla VenumadhavGoel SwatiNischal SangeetaHeuck ChristophVivek KumarDas BhaskarVerma Amit<p>Abstract</p> <p>Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.</p>http://www.jhoonline.org/content/2/1/36 |
| spellingShingle | Kotla Venumadhav Goel Swati Nischal Sangeeta Heuck Christoph Vivek Kumar Das Bhaskar Verma Amit Mechanism of action of lenalidomide in hematological malignancies Journal of Hematology & Oncology |
| title | Mechanism of action of lenalidomide in hematological malignancies |
| title_full | Mechanism of action of lenalidomide in hematological malignancies |
| title_fullStr | Mechanism of action of lenalidomide in hematological malignancies |
| title_full_unstemmed | Mechanism of action of lenalidomide in hematological malignancies |
| title_short | Mechanism of action of lenalidomide in hematological malignancies |
| title_sort | mechanism of action of lenalidomide in hematological malignancies |
| url | http://www.jhoonline.org/content/2/1/36 |
| work_keys_str_mv | AT kotlavenumadhav mechanismofactionoflenalidomideinhematologicalmalignancies AT goelswati mechanismofactionoflenalidomideinhematologicalmalignancies AT nischalsangeeta mechanismofactionoflenalidomideinhematologicalmalignancies AT heuckchristoph mechanismofactionoflenalidomideinhematologicalmalignancies AT vivekkumar mechanismofactionoflenalidomideinhematologicalmalignancies AT dasbhaskar mechanismofactionoflenalidomideinhematologicalmalignancies AT vermaamit mechanismofactionoflenalidomideinhematologicalmalignancies |